9.30
-0.32(-3.33%)
Currency In USD
| Previous Close | 9.62 |
| Open | 9.7 |
| Day High | 9.93 |
| Day Low | 9.22 |
| 52-Week High | 29.61 |
| 52-Week Low | 5.9 |
| Volume | 2.32M |
| Average Volume | 2M |
| Market Cap | 682.78M |
| PE | -9.21 |
| EPS | -1.01 |
| Moving Average 50 Days | 7.7 |
| Moving Average 200 Days | 10.49 |
| Change | -0.32 |
If you invested $1000 in Arvinas, Inc. (ARVN) since IPO date, it would be worth $579.44 as of October 08, 2025 at a share price of $9.3. Whereas If you bought $1000 worth of Arvinas, Inc. (ARVN) shares 5 years ago, it would be worth $355.64 as of October 08, 2025 at a share price of $9.3.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®
GlobeNewswire Inc.
Oct 05, 2025 6:00 PM GMT
– ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson’s disease – – ARV-102 demonstrated dose-dependent cerebrospinal fluid (CSF) exposure in subjects in both trials – – After 14 days of treatment in
Arvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®
GlobeNewswire Inc.
Oct 01, 2025 11:00 AM GMT
NEW HAVEN, Conn., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that two presentations, including one e-po
Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation
GlobeNewswire Inc.
Sep 17, 2025 8:30 PM GMT
Arvinas and Pfizer plan to jointly select third party for the out-licensing and commercialization of vepdegestrant Additional cost optimization measures expected to realize total annual savings of more than $100 million compared to FY 2024 Board auth